Australia markets closed

    +15.50 (+0.20%)

    -0.0032 (-0.44%)
  • ASX 200

    +19.10 (+0.26%)
  • OIL

    +1.21 (+1.47%)
  • GOLD

    -5.40 (-0.31%)

    -350.08 (-0.42%)
  • CMC Crypto 200

    +49.62 (+3.61%)

2021 Allergic Conjunctivitis Report on Drugs in Development -

·4-min read

DUBLIN, September 23, 2021--(BUSINESS WIRE)--The "Allergic Conjunctivitis (Ophthalmology) - Drugs In Development, 2021" report has been added to's offering.

This report provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape. Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.

This report provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 6, 2, 12 and 1 respectively.

Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis (Ophthalmology).

  • The pipeline guide reviews pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Allergic Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Allergic Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews the latest news related to pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Allergic Conjunctivitis (Ophthalmology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Allergic Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

  • AbbVie Inc

  • Accolade Pharmaceuticals LLC

  • Ajanta Pharma Ltd

  • Aldeyra Therapeutics Inc

  • Alexion Pharmaceuticals Inc

  • ALK-Abello AS

  • Allakos Inc

  • Clevexel Pharma SA

  • Faes Farma SA

  • IACTA Pharmaceuticals Inc

  • Intas Pharmaceuticals Ltd

  • JW Pharmaceutical Corp

  • Kissei Pharmaceutical Co Ltd

  • Nanomerics Ltd

  • NicOx SA

  • Ocular Therapeutix Inc

  • OKYO Pharma Ltd

  • Oyster Point Pharma Inc

  • Quark Pharmaceuticals Inc

  • RAPT Therapeutics Inc

  • Re-Pharm Ltd

  • Satellos Bioscience Inc

  • SIFI SpA

  • Sylentis SAU

  • Vanda Pharmaceuticals Inc

  • Wuhan Yicheng Biotechnology Co Ltd

For more information about this report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting